From the Eye to the Brain
Are stratification studies the key to identifying patients at risk of dementia?
Pearse Keane, Siegfried Wagner | | Quick Read
Estimates suggest that 50 million people were living with dementia in 2017. With the progressive aging of the population, the number is predicted to reach 75 million by 2030. Yet it has been noted that 50 to 80 percent of cases remain undiagnosed in high income-countries. Why? Part of the issue lies with the logistics of making a diagnosis. The gold standard for the most common form of dementia, Alzheimer’s disease, has classically been neuropathological confirmation, post-mortem. Research into newer techniques, such as amyloid positron emission tomography (PET) scanning and cerebrospinal fluid analysis, has supported their utility as potential biomarkers; however, these tests are invasive, expensive, and not pragmatic on a large scale. Could assessment of the neurosensory retina – derived embryologically from the same tissue – be the answer?
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine